N6-(4-fluorobenzyl)-N4-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine

ID: ALA5200865

PubChem CID: 168290206

Max Phase: Preclinical

Molecular Formula: C16H15FN8

Molecular Weight: 338.35

Names and Identifiers

Canonical SMILES:  Cc1cc(Nc2nc(NCc3ccc(F)cc3)nc3[nH]ncc23)n[nH]1

Standard InChI:  InChI=1S/C16H15FN8/c1-9-6-13(24-23-9)20-14-12-8-19-25-15(12)22-16(21-14)18-7-10-2-4-11(17)5-3-10/h2-6,8H,7H2,1H3,(H4,18,19,20,21,22,23,24,25)

Standard InChI Key:  CTKWGPSDOQLVKK-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
   -1.7907   -0.0341    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0761    0.3781    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3642   -0.0337    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3642   -0.8589    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0743   -1.2707    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7907   -0.8626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5981   -1.1138    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0708   -0.4575    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5768    0.2127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3503   -1.2715    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0650   -0.8589    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7796   -1.2715    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4944   -0.8590    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2065   -1.2711    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2065   -2.0965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4962   -2.5084    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7796   -2.1002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0761    1.2033    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7907    1.6159    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5054    1.2033    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1241    1.7747    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7934    2.5091    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9692    2.4168    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9211    1.5611    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9211   -2.5091    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  6  5  2  0
  1  6  1  0
  6  7  1  0
  7  8  1  0
  9  8  2  0
  1  9  1  0
  4 10  1  0
 10 11  1  0
 11 12  1  0
 13 12  2  0
 14 13  1  0
 15 14  2  0
 16 15  1  0
 17 16  2  0
 12 17  1  0
  2 18  1  0
 18 19  1  0
 20 19  1  0
 20 21  2  0
 21 22  1  0
 23 22  1  0
 19 23  2  0
 21 24  1  0
 15 25  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5200865

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 338.35

Molecular Weight (Monoisotopic): 338.1404

AlogP: 2.88

#Rotatable Bonds: 5

Polar Surface Area: 107.20

Molecular Species: NEUTRAL

HBA: 6

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 8.89

CX Basic pKa: 3.43

CX LogP: 2.89

CX LogD: 2.88

Aromatic Rings: 4

Heavy Atoms: 25

QED Weighted: 0.45

Np Likeness Score: -1.98

References

1. Sun Y, Sun Y, Wang L, Wu T, Yin W, Wang J, Xue Y, Qin Q, Sun Y, Yang H, Zhao D, Cheng M..  (2022)  Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.,  238  [PMID:35576702] [10.1016/j.ejmech.2022.114424]

Source

Source(1):

• Scientific Literature